First Phase II milestone reached for NovaBay's 3-in-1 antimicrobial auriclosene
This article was originally published in Scrip
Executive Summary
NovaBay Pharmaceuticals is attacking antibiotic resistance with three different formulations of a single novel product, auriclosene (NVC-422), and plans to move into Phase III development of an irrigation solution during the first half of 2014 based on positive Phase II results in the prevention of urinary catheter blockage and encrustation (UCBE).